Q2 FY2026 · ended Jun 30, 2026 · Revenue $0 · Filed Aug 11, 2026
Inhibikase Therapeutics, Inc. (IKT) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $0 and a net loss of $19.6 million. Free cash flow was -$12.4 million.
Revenue
$0
Net income
$-19.59M
-97.6% vs year-ago quarter
Operating cash flow
$-12.44M
-123.2% vs year-ago quarter
Free cash flow
$-12.44M
-123.2% vs year-ago quarter
EPS
$-0.11
+0.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
139.54M
+87.3% vs year-ago quarter
Net cash
$87.63M
Q2 FY2025
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- IKT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Wilmington, DE
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1750149
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | — | $0 | $0 |
| Operating income | -$21.1M | -$17.8M | -$13.8M | -$12.8M | -$10.8M |
| Net income | -$19.6M | -$16.4M | -$12.7M | -$11.9M | -$9.9M |
| Diluted EPS | -$0.11 | -$0.10 | -$0.10 | -$0.13 | -$0.11 |
| Operating cash flow | -$12.4M | -$12.1M | -$7.5M | -$10.6M | -$5.6M |
| Free cash flow | -$12.4M | -$12.1M | -$7.5M | -$10.6M | -$5.6M |
| Total assets | $163.6M | $173.3M | $181.2M | $79.6M | $88.9M |
| Total liabilities | $10.3M | $5.7M | $8.3M | $6.7M | $8.8M |
| Stockholders' equity | $153.3M | $167.6M | $172.9M | $72.9M | $80.1M |
| Cash and investments | $159.0M | $170.4M | $178.8M | $77.3M | $87.7M |
| Total debt | — | — | — | — | $37,944 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Oct 20, 2026 | Oct 19, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 8, 2026 | Sep 8, 2026 |
| 8-K |
Current report
Auditor change
|
Aug 26, 2026 | Aug 21, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Unregistered share sale
|
Jul 29, 2026 | Jul 29, 2026 |
All 368 Inhibikase Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.